Prelude Therapeutics Incorporated (PRLD)
Prelude Therapeutics Incorporated at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Prelude Therapeutics Incorporated (PRLD) is a Biotechnology company based in US with a market capitalization of $230M. Free cash flow was negative at -$56.4M. This page tracks PRLD's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 131 employees · IPO Sep 25, 2020
Valuation
Valuation & price
$4.48as of May 17, 2026· -18.8% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
3.35
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$230M
Market cap
—
Revenue growth (YoY)
85.9%
Gross margin
-$56.4M
Free cash flow (USD)
-$85.4M
Net debt
Net cash position
1.5%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Gross margin by year
2024 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 10, 2026Filing
Annual Meeting Results
- 8-K eventMay 12, 2026Filing
Financial Results and Update
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- Insider buyApr 23, 2026Filing
Insider Buy $12.5MORBIMED ADVISORS LLC · Director, 10% Owner · $12.5M
- Insider buyApr 23, 2026Filing
Insider Buy $12.5MBonita David P · Director, 10% Owner · $12.5M
- 8-K eventApr 21, 2026Filing
Stock Offering
- 8-K eventApr 20, 2026Filing
Corporate Presentation
- 8-K eventApr 15, 2026Filing
Chief Medical Officer Appointment
Questions
Frequently asked questions
What is Prelude Therapeutics Incorporated's market cap?
Prelude Therapeutics Incorporated (PRLD) has a market capitalization of $230M.
What is PRLD's P/E ratio?
A meaningful P/E ratio is not available for PRLD — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is PRLD's price-to-book (P/B) ratio?
PRLD trades at 3.35 times book value per share.
Are insiders buying PRLD stock?
SEC Form 4 filings show no open-market insider buys at Prelude Therapeutics Incorporated in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.